|
Intellectual Disability
|
0.310 |
GeneticVariation
|
group |
BEFREE |
We now report 16 individuals with mild to profound ID and DD and a de novo mutation in PPP2CA, encoding the catalytic Cα subunit.
|
30595372 |
2019 |
|
Intellectual Disability
|
0.310 |
Biomarker
|
group |
GENOMICS_ENGLAND |
We now report 16 individuals with mild to profound ID and DD and a de novo mutation in PPP2CA, encoding the catalytic Cα subunit.
|
30595372 |
2019 |
|
Heart Diseases
|
0.300 |
Biomarker
|
group |
CTD_human |
Overexpression of the catalytic subunit of protein phosphatase 2A impairs cardiac function.
|
15247211 |
2004 |
|
Language Disorders
|
0.300 |
Biomarker
|
group |
GENOMICS_ENGLAND |
De Novo Mutations Affecting the Catalytic Cα Subunit of PP2A, PPP2CA, Cause Syndromic Intellectual Disability Resembling Other PP2A-Related Neurodevelopmental Disorders.
|
30595372 |
2019 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Furthermore, in human breast cancer samples, PP2Ac expression is negatively correlated with the phosphorylation of Girdin, and low expression of PP2Ac is correlated with tumor stage, grade and lymph node metastasis of breast cancer.
|
30935690 |
2019 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
We have previously shown that alterations in Arl2 protein content were associated with corresponding modifications of the tumor suppressor PP2Ac protein content in breast cancer cells.
|
18818514 |
2008 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the downregulated expression of PPP2CA was significantly correlated with tumor stage and Gleason grade.
|
17977648 |
2008 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Metformin treatment also significantly reduced tumor formation in vivo as well as protein expression of PCNA, Akt, Myc, and serine phosphorylation of the latter 2, which can be partially blocked by O/E α4 or sh-PP2Ac.
|
30693913 |
2019 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Association between PPP2CA expression and colorectal cancer prognosis tumor marker prognostic study.
|
30296597 |
2018 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model.
|
24642616 |
2014 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
DBTC promoted xenograft growth and metastasis, induced tumor-associated macrophage infiltration, promoted angiogenesis, activated the nuclear factor-κB (NF-κB) pathway, and repressed PP2Ac expression.
|
26761431 |
2016 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The latter notion implies that PP2Calpha may possess tumor-suppressing properties, and it thereby sets the stage for more elaborate analyses on its involvement in the development and progression of cancer.
|
17941990 |
2007 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Accumulating evidence links PP2Ac methylation to diseases, including cancer and neurodegenerative disorders.
|
30186749 |
2018 |
|
Malignant Neoplasms
|
0.030 |
PosttranslationalModification
|
group |
BEFREE |
Therefore, disruption of PP2Ac methylation may contribute to cancer, and modulation of this methylation may serve as an anticancer target.
|
22904676 |
2012 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
The latter notion implies that PP2Calpha may possess tumor-suppressing properties, and it thereby sets the stage for more elaborate analyses on its involvement in the development and progression of cancer.
|
17941990 |
2007 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Accumulating evidence links PP2Ac methylation to diseases, including cancer and neurodegenerative disorders.
|
30186749 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
PosttranslationalModification
|
group |
BEFREE |
Therefore, disruption of PP2Ac methylation may contribute to cancer, and modulation of this methylation may serve as an anticancer target.
|
22904676 |
2012 |
|
Immune System Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Furthermore, the minor allele of PPP2CA rs10491322 as a risk factor was correlated with immunologic disorders for SLE.
|
29979448 |
2018 |
|
Liver neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Injection of the carcinogen, diethylnitrosamine, induced significantly more and larger liver tumors in HCV transgenic mice that overexpress PP2Ac compared with control mice.
|
23901063 |
2014 |
|
Neurodegenerative Disorders
|
0.010 |
PosttranslationalModification
|
group |
BEFREE |
Accumulating evidence links PP2Ac methylation to diseases, including cancer and neurodegenerative disorders.
|
30186749 |
2018 |
|
Neurodevelopmental Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Overall, we found that pathogenic PPP2CA variants impair PP2A-B56(δ) functionality, suggesting that PP2A-related neurodevelopmental disorders constitute functionally converging ID syndromes.
|
30595372 |
2019 |
|
Seizures
|
0.400 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Seizures
|
0.400 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
De Novo Mutations Affecting the Catalytic Cα Subunit of PP2A, PPP2CA, Cause Syndromic Intellectual Disability Resembling Other PP2A-Related Neurodevelopmental Disorders.
|
30595372 |
2019 |
|
Feeding difficulties
|
0.400 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
De Novo Mutations Affecting the Catalytic Cα Subunit of PP2A, PPP2CA, Cause Syndromic Intellectual Disability Resembling Other PP2A-Related Neurodevelopmental Disorders.
|
30595372 |
2019 |
|
Feeding difficulties
|
0.400 |
Biomarker
|
phenotype |
HPO |
|
|
|